Psoriatic Arthritis Acceptable Symptoms State: Does Sex Make a Difference?
Clinical outcomes
Patient Acceptable Symptoms State (PASS)
Psoriatic arthritis
Sex differences
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
13 Jul 2024
13 Jul 2024
Historique:
received:
07
05
2024
accepted:
25
06
2024
medline:
14
7
2024
pubmed:
14
7
2024
entrez:
13
7
2024
Statut:
aheadofprint
Résumé
The Patient Acceptable Symptoms State (PASS) is a validated instrument that is used to assess whether a patient with psoriatic arthritis (PsA) accepts her/his disease status by asking them a simple question: "Think about all the ways your PsA has affected you during the last 48 h. If you were to remain in the next few months as you were during the last 48 h, would this be acceptable to you?" The aim of the present study was to explore any PASS differences in patients with PsA based on sex by looking at the corresponding thresholds of Disease Activity for Psoriatic Arthritis (DAPSA), Psoriatic Arthritis Impact of the Disease-12 (PsAID-12) and the Health Assessment Questionnaire-Disability Index (HAQ-DI) in female and male patients. This was a cross-sectional study that included two PsA cohorts. To identify the DAPSA, PsAID and HAQ-DI thresholds that differentiated patients who reported "yes" in response to the PASS question from those who reported "no," we used the receiver operating characteristic curves both for the female and male sexes. Moreover, Cohen's kappa test was used to determine the agreement of a PASS "yes" with DAPSA ≤ 14, PsAID ≤ 4 and HAQ-DI ≤ 0.5. Three-hundred ten patients were considered for the study. The DAPSA, PsAID-12 and HAQ-DI thresholds that differentiated PASS "yes" patients from PASS "no" patients were 11.7, 1.85 and 0.625 in male patients and 13.3, 3.85 and 0.750 in female patients, respectively. A PASS "yes" and DAPSA ≤ 14 showed moderate agreement in males (kappa = 0.56) and good agreement in females (kappa = 0.80); the agreement between a PASS "yes" and PsAID ≤ 4 and between a PASS "yes" and HAQ-DI ≤ 0.5 was higher in female patients (moderate). Female patients accept their disease at higher DAPSA, PsAID and HAQ-DI values than male patients do. The clinical meaning of this could be that a female patient generally has a greater global disease acceptance inclination. Therefore, this study further supports the concept that sex differences are present in patients with PsA.
Identifiants
pubmed: 39003339
doi: 10.1007/s40744-024-00698-7
pii: 10.1007/s40744-024-00698-7
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957–70. https://doi.org/10.1056/NEJMra1505557 .
doi: 10.1056/NEJMra1505557
pubmed: 28273019
Scarpa R, Ayala F, Caporaso N, Olivieri I. Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol. 2006;33:210–2. PMID: 16465649.
Lubrano E, Scriffignano S, Perrotta FM. Psoriatic arthritis, psoriatic disease, or psoriatic syndrome? J Rheumatol. 2019;46:1428–30. https://doi.org/10.3899/jrheum.190054 . PMID: 31676545.
Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64:14–7.
Richette P, Vis M, Ohrndorf S, et al. Identification of PsA phenotypes with machine learning analytics using data from two phase III clinical trials of guselkumab in a bio-naïve population of patients with PsA. RMD Open. 2023;9: e002934.
doi: 10.1136/rmdopen-2022-002934
pubmed: 37001920
pmcid: 10069583
Lubrano E, Perrotta FM. Sex-related differences in psoriatic arthritis. Lancet Rheumatol. 2024;5:699–701.
doi: 10.1016/S2665-9913(23)00274-6
Eder L, Mylvaganam S, Pardo Pardo J, et al. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis. Lancet Rheumatol. 2024;5:716–27.
doi: 10.1016/S2665-9913(23)00264-3
Lubrano E, Scriffignano S, Fatica M, et al. Psoriatic arthritis in males and females: differences and similarities. Rheumatol Ther. 2023;10:589–99. https://doi.org/10.1007/s40744-023-00535-3 .
doi: 10.1007/s40744-023-00535-3
pubmed: 36795290
pmcid: 10140210
Mogil JS. Qualitative sex differences in pain processing: emerging evidence of a biased literature. Nat Rev Neurosci. 2020;21:353–65. https://doi.org/10.1038/s41583-020-0310-6 .
doi: 10.1038/s41583-020-0310-6
pubmed: 32440016
Lubrano E, Scriffignano S, Azuaga AB, et al. Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices. RMD Open. 2020;6: e001170. https://doi.org/10.1136/rmdopen-2020-001170 .
doi: 10.1136/rmdopen-2020-001170
pubmed: 32179713
pmcid: 7076266
Fei JZ, Perruccio AV, Ye JY, Gladman DD, Chandran V. The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis. Rheumatology (Oxford). 2020;59:69–76. https://doi.org/10.1093/rheumatology/kez202 .
doi: 10.1093/rheumatology/kez202
pubmed: 31199486
Rovner GS, Sunnerhagen KS, Björkdahl A, Gerdle B, Börsbo B, Johansson F, Gillanders D. Chronic pain and sex-differences; women accept and move, while men feel blue. PLoS ONE. 2017;12: e0175737. https://doi.org/10.1371/journal.pone.0175737 .
doi: 10.1371/journal.pone.0175737
pubmed: 28441403
pmcid: 5404887
Lubrano E, Perrotta FM, Parsons WJ, Marchesoni A. Patient’s global assessment as an outcome measure for psoriatic arthritis in clinical practice: a surrogate for measuring low disease activity? J Rheumatol. 2015;42:2332–8. https://doi.org/10.3899/jrheum.150595 .
doi: 10.3899/jrheum.150595
pubmed: 26523033
Ogdie A, Coates LC, Mease P. Measuring outcomes in psoriatic arthritis. Arthritis Care Res (Hoboken). 2020;72(Suppl 10):82–109. https://doi.org/10.1002/acr.24242 .
doi: 10.1002/acr.24242
pubmed: 33091263